ARCHIVES

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

New Abiraterone Acetate Results Show Greater Benefit Than Before

June 24, 2011

Senate Increases NIH Funding for 2013, Rejects President’s $200+ Million Increase for Program Evaluation Activities

June 22, 2012

Proposed FDA Charges For NDA Drugs, Biologics Submissions Would Total $76 Million In FY 1990

January 27, 1989

Funding Opportunities

September 27, 2002

Pancreatic Cancer Research To Increase, Institute Says.

November 16, 2001

Environmental Emphasis Urged, Including New Role For Comp Centers NCAB Unenthusiastic

March 21, 1975